A Phase 3 interventional study of Axitinib and Placebo in Clear Cell Renal Carcinoma, sponsored by SFJ Pharma Ltd. II. Terminated at 106 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-20.
Sponsored by SFJ Pharma Ltd. II · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.
Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 4th largest by enrollment, is one of 3 that started in 2012, is one of 5 in phase 3, and was the 6th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
Stephanie Berg · Sites in United States
Ages 18+
Tianjin Medical University Second Hospital · Sites in China
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–80
By country, each count listing its studies:
Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 31 · Phase 3 5
First in 2006; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 724 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 41 interventional studies. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 41 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with SFJ Pharma Ltd. II as lead sponsor.
SFJ Pharma Ltd. II has 1 study filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
2 of the studies testing axitinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07159191Peking Union Medical College HospitalEnvafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | 2027-02-20 |
| NCT07123090Stephanie BergA Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies testing axitinib in Carcinoma, Renal Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.
This is a prospective, randomized, double blind placebo controlled Phase 3 trial of oral axitinib starting at 5 mg twice daily given 3 years vs. placebo.
Approximately 700 patients will be randomized in a 1:1 ratio between axitinib vs placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must be treated by nephrectomy and patients must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
Patients must be diagnosed with one of the following based on American Joint Committee on Cancer (AJCC) TNM staging version 2010, Eastern Collaborative Oncology Group () performance status (PS):
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Axitinib
Drug: Placebo
Axitinib 5 mg twice daily
Also known as: Inlyta
Placebo twice daily
Disease Free Survival (DFS) as Assessed by Blinded Independent Review Committee (IRC)
DFS is defined as time interval from the date of randomization to first date of recurrence/relapse (distant or local recurrence of \[RCC\] or occurrence of a secondary malignancy {occurrence of a second primary cancer other than RCC} or death). For participants with no DFS event, DFS was censored at date of last scan prior to time of analyses. Participants alive who did not have post-baseline disease assessments, DFS was censored at randomization. Participants who received further anti-tumor therapy prior to recurrence or occurrence of a secondary malignancy or death, DFS was censored on date of last scan prior to taking anti-tumor medication. Participants who missed 2 or more consecutive tumor scans immediately followed by an event were censored at date of last objective tumor assessment prior to missing/not readable scan.
Time frame: From randomization date up to first date of recurrence or the occurrence of a secondary malignancy or death (up to 5 years)
Overall Survival (OS)
OS defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. Participants lacking data beyond randomization had their survival times censored at randomization.
Time frame: From randomization date until death due to any cause (up to 5 years)
Number of Participants With Treatment-Emergent Adverse Events (AE) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: From Day 1 up to 28 days after last dose (maximum duration of 3 years)
Number of Participants With Treatment-Emergent Treatment Related Adverse Events and Serious Adverse Events (SAEs)
A treatment related AE is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness was judged by investigator. AEs included both serious and non-serious adverse events.
Time frame: From Day 1 up to 28 days after last dose (maximum duration of 3 years)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) By Severity
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AE was assessed according to severity as: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
Time frame: From Day 1 up to 28 days after last dose (maximum duration of 3 years)
Number of Participants With Laboratory Abnormalities By Maximum CTCAE Grade: Hematology
Hematology parameters included anemia, hemoglobin increased, lymphocyte count increased, lymphocyte count decreased, neutrophil count decreased, platelet count decreased, and white blood cell count decreased. CTCAE grades: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
Time frame: From Day 1 up to 28 days after last dose (maximum duration of 3 years)
Number of Participants With Laboratory Abnormalities By Maximum CTCAE Grade: Chemistry
Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase increased, creatinine increased, hypoalbuminemia, hypercalcemia, hypocalcemia, hyperglycemia, hypoglycemia, hyperkalemia, hypokalemia, hypernatremia, hyponatremia. CTCAE grades: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
Time frame: From Day 1 up to 28 days after last dose (maximum duration of 3 years)
Number of Participants With Laboratory Abnormalities: Thyroid Function
Number of participants with thyrotropin levels: \<5 milli-international units per litre (mIU/L), \>=5 to \<10 mIU/L, \>=10 mIU/L are reported.
Time frame: From Day 1 up to 28 days after last dose (maximum duration of 3 years)
Number of Participants With Laboratory Abnormalities: Urinalysis
Number of participants with urine protein dipstick grading: negative/trace (5 to 20 milligram per deciliter \[mg/dL\]), 1+ (30 mg/dL\]), 2+ (100 mg/dL), 3+ (300 mg/dL) and 4+ (more than 1000 mg/dL) are reported.
Time frame: From Day 1 up to 28 days after last dose (maximum duration of 3 years)
A total of 128 study sites in 9 countries randomized 724 participants into this study.
| Milestone | Axitinib | Placebo |
|---|---|---|
| Started | 363 | 361 |
| Treated | 360 | 360 |
| Completed | 0 | 1 |
| Not completed | 363 | 360 |
| Withdrew: Anticancer therapy need not in protocol | 5 | 2 |
| Withdrew: Participant noncompliance | 4 | 4 |
| Withdrew: Lost to follow-up | 13 | 6 |
| Withdrew: Death | 31 | 33 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Investigator decision | 1 | 3 |
| Withdrew: Withdrawal by subject | 24 | 25 |
| Withdrew: Study terminated by sponsor | 282 | 285 |
DFS is defined as time interval from the date of randomization to first date of recurrence/relapse (distant or local recurrence of \[RCC\] or occurrence of a secondary malignancy {occurrence of a second primary cancer other than RCC} or death). For participants with no DFS event, DFS was censored at date of last scan prior to time of analyses. Participants alive who did not have post-baseline disease assessments, DFS was censored at randomization. Participants who received further anti-tumor therapy prior to recurrence or occurrence of a secondary malignancy or death, DFS was censored on date of last scan prior to taking anti-tumor medication. Participants who missed 2 or more consecutive tumor scans immediately followed by an event were censored at date of last objective tumor assessment prior to missing/not readable scan.
| years | Axitinib | Placebo |
|---|---|---|
| Disease Free Survival (DFS) as Assessed by Blinded Independent Review Committee (IRC) | NA (4.1 to NA) | NA (4.1 to NA) |
OS defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. Participants lacking data beyond randomization had their survival times censored at randomization.
| years | Axitinib | Placebo |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.
| Participants | Axitinib | Placebo |
|---|---|---|
| AEs | 353 | 333 |
| SAEs | 75 | 54 |
A treatment related AE is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness was judged by investigator. AEs included both serious and non-serious adverse events.
| Participants | Axitinib | Placebo |
|---|---|---|
| Treatment Related AEs | 326 | 202 |
| Treatment Related SAEs | 27 | 9 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AE was assessed according to severity as: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
| Participants | Axitinib | Placebo |
|---|---|---|
| Grade 1 | 23 | 69 |
| Grade 2 | 108 | 152 |
| Grade 3 | 208 | 103 |
| Grade 4 | 12 | 8 |
| Grade 5 | 2 | 1 |
Hematology parameters included anemia, hemoglobin increased, lymphocyte count increased, lymphocyte count decreased, neutrophil count decreased, platelet count decreased, and white blood cell count decreased. CTCAE grades: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
| Participants | Axitinib | Placebo |
|---|---|---|
| Anemia — Grade 1 | 256 | 233 |
| Anemia — Grade 2 | 87 | 114 |
| Anemia — Grade 3 | 8 | 6 |
| Anemia — Grade 4 | 0 | 2 |
| Anemia — Grade 5 | 0 | 0 |
| Hemoglobin increased — Grade 1 | 328 | 354 |
| Hemoglobin increased — Grade 2 | 23 | 1 |
| Hemoglobin increased — Grade 3 | 0 | 0 |
| Hemoglobin increased — Grade 4 | 0 | 0 |
| Hemoglobin increased — Grade 5 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 | 305 | 282 |
| Lymphocyte count decreased — Grade 2 | 26 | 39 |
| Lymphocyte count decreased — Grade 3 | 19 | 33 |
| Lymphocyte count decreased — Grade 4 | 1 | 1 |
| Lymphocyte count decreased — Grade 5 | 0 | 0 |
| Lymphocyte count increased — Grade 1 | 343 | 339 |
| Lymphocyte count increased — Grade 2 | 0 | 0 |
| Lymphocyte count increased — Grade 3 | 8 | 16 |
| Lymphocyte count increased — Grade 4 | 0 | 0 |
| Lymphocyte count increased — Grade 5 | 0 | 0 |
| Neutrophil count decreased — Grade 1 | 284 | 299 |
| Neutrophil count decreased — Grade 2 | 48 | 45 |
| Neutrophil count decreased — Grade 3 | 19 | 8 |
| Neutrophil count decreased — Grade 4 | 0 | 3 |
| Neutrophil count decreased — Grade 5 | 0 | 0 |
| Platelet count decreased — Grade 1 | 267 | 303 |
| Platelet count decreased — Grade 2 | 77 | 49 |
| Platelet count decreased — Grade 3 | 5 | 1 |
| Platelet count decreased — Grade 4 | 0 | 1 |
| Platelet count decreased — Grade 5 | 0 | 0 |
| White blood cell count decreased — Grade 1 | 288 | 281 |
| White blood cell count decreased — Grade 2 | 55 | 67 |
| White blood cell count decreased — Grade 3 | 8 | 6 |
| White blood cell count decreased — Grade 4 | 0 | 1 |
| White blood cell count decreased — Grade 5 | 0 | 0 |
Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase increased, creatinine increased, hypoalbuminemia, hypercalcemia, hypocalcemia, hyperglycemia, hypoglycemia, hyperkalemia, hypokalemia, hypernatremia, hyponatremia. CTCAE grades: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE).
| Participants | Axitinib | Placebo |
|---|---|---|
| Alanine aminotransferase increased — Grade 1 | 1 | 2 |
| Alanine aminotransferase increased — Grade 2 | 0 | 3 |
| Alanine aminotransferase increased — Grade 3 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 | 1 | 1 |
| Alanine aminotransferase increased — Grade 5 | 0 | 0 |
| Alkaline phosphatase increased, — Grade 1 | 298 | 316 |
| Alkaline phosphatase increased, — Grade 2 | 53 | 37 |
| Alkaline phosphatase increased, — Grade 3 | 0 | 2 |
| Alkaline phosphatase increased, — Grade 4 | 0 | 0 |
| Alkaline phosphatase increased, — Grade 5 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 | 0 | 1 |
| Aspartate aminotransferase increased — Grade 2 | 2 | 1 |
| Aspartate aminotransferase increased — Grade 3 | 1 | 3 |
| Aspartate aminotransferase increased — Grade 4 | 0 | 1 |
| Aspartate aminotransferase increased — Grade 5 | 0 | 0 |
| Blood bilirubin increased — Grade 1 | 315 | 330 |
| Blood bilirubin increased — Grade 2 | 30 | 18 |
| Blood bilirubin increased — Grade 3 | 6 | 6 |
| Blood bilirubin increased — Grade 4 | 0 | 1 |
| Blood bilirubin increased — Grade 5 | 0 | 0 |
| Creatine phosphokinase increased — Grade 1 | 0 | 0 |
| Creatine phosphokinase increased — Grade 2 | 0 | 0 |
| Creatine phosphokinase increased — Grade 3 | 0 | 0 |
| Creatine phosphokinase increased — Grade 4 | 2 | 1 |
| Creatine phosphokinase increased — Grade 5 | 0 | 1 |
| Creatinine increased — Grade 1 | 13 | 7 |
| Creatinine increased — Grade 2 | 274 | 301 |
| Creatinine increased — Grade 3 | 60 | 46 |
| Creatinine increased — Grade 4 | 3 | 0 |
| Creatinine increased — Grade 5 | 1 | 1 |
| Hypoalbuminemia — Grade 1 | 347 | 348 |
| Hypoalbuminemia — Grade 2 | 4 | 5 |
| Hypoalbuminemia — Grade 3 | 0 | 2 |
| Hypoalbuminemia — Grade 4 | 0 | 0 |
| Hypoalbuminemia — Grade 5 | 0 | 0 |
| Hypercalcemia — Grade 1 | 335 | 344 |
| Hypercalcemia — Grade 2 | 16 | 11 |
| Hypercalcemia — Grade 3 | 0 | 0 |
| Hypercalcemia — Grade 4 | 0 | 0 |
| Hypercalcemia — Grade 5 | 0 | 0 |
| Hypocalcemia — Grade 1 | 280 | 266 |
| Hypocalcemia — Grade 2 | 64 | 85 |
| Hypocalcemia — Grade 3 | 3 | 4 |
| Hypocalcemia — Grade 4 | 2 | 0 |
| Hypocalcemia — Grade 5 | 2 | 0 |
| Hyperglycemia — Grade 1 | 116 | 115 |
| Hyperglycemia — Grade 2 | 160 | 159 |
| Hyperglycemia — Grade 3 | 62 | 56 |
| Hyperglycemia — Grade 4 | 12 | 23 |
| Hyperglycemia — Grade 5 | 1 | 2 |
| Hypoglycemia — Grade 1 | 230 | 246 |
| Hypoglycemia — Grade 2 | 111 | 101 |
| Hypoglycemia — Grade 3 | 9 | 6 |
| Hypoglycemia — Grade 4 | 0 | 1 |
| Hypoglycemia — Grade 5 | 1 | 1 |
| Hyperkalemia — Grade 1 | 318 | 325 |
| Hyperkalemia — Grade 2 | 1 | 0 |
| Hyperkalemia — Grade 3 | 26 | 21 |
| Hyperkalemia — Grade 4 | 6 | 9 |
| Hyperkalemia — Grade 5 | 0 | 0 |
| Hypokalemia — Grade 1 | 340 | 348 |
| Hypokalemia — Grade 2 | 9 | 7 |
| Hypokalemia — Grade 3 | 0 | 0 |
| Hypokalemia — Grade 4 | 2 | 0 |
| Hypokalemia — Grade 5 | 0 | 0 |
| Hypernatremia — Grade 1 | 245 | 245 |
| Hypernatremia — Grade 2 | 96 | 94 |
| Hypernatremia — Grade 3 | 8 | 14 |
| Hypernatremia — Grade 4 | 2 | 2 |
| Hypernatremia — Grade 5 | 0 | 0 |
| Hyponatremia — Grade 1 | 331 | 338 |
| Hyponatremia — Grade 2 | 13 | 11 |
| Hyponatremia — Grade 3 | 0 | 0 |
| Hyponatremia — Grade 4 | 7 | 5 |
| Hyponatremia — Grade 5 | 0 | 1 |
Number of participants with thyrotropin levels: \<5 milli-international units per litre (mIU/L), \>=5 to \<10 mIU/L, \>=10 mIU/L are reported.
| Participants | Axitinib | Placebo |
|---|---|---|
| <5 mIU/L | 160 | 308 |
| >=5 - <10 mIU/L | 105 | 37 |
| >=10 mIU/L | 86 | 11 |
Number of participants with urine protein dipstick grading: negative/trace (5 to 20 milligram per deciliter \[mg/dL\]), 1+ (30 mg/dL\]), 2+ (100 mg/dL), 3+ (300 mg/dL) and 4+ (more than 1000 mg/dL) are reported.
| Participants | Axitinib | Placebo |
|---|---|---|
| Negative/trace | 135 | 237 |
| 1+ | 88 | 84 |
| 2+ | 74 | 24 |
| 3+ | 49 | 8 |
| 4+ | 5 | 2 |
Collected over From Day 1 up to 28 days after last dose (maximum duration of 3 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib | 31/360 (8.6%) | 75/360 (20.8%) | 353/360 (98.1%) |
| Placebo | 33/360 (9.2%) | 54/360 (15%) | 332/360 (92.2%) |
| Event | Axitinib | Placebo |
|---|---|---|
| CholecystitisHepatobiliary disorders | 5/360 | 1/360 |
| Acute Coronary SyndromeCardiac disorders | 3/360 | 0/360 |
| Acute Myocardial InfarctionCardiac disorders | 3/360 | 1/360 |
| Angina PectorisCardiac disorders | 2/360 | 0/360 |
| Cardiac Failure CongestiveCardiac disorders | 2/360 | 0/360 |
| Abdominal PainGastrointestinal disorders | 2/360 | 0/360 |
| DiarrhoeaGastrointestinal disorders | 2/360 | 0/360 |
| Large Intestine PolypGastrointestinal disorders | 0/360 | 2/360 |
| Pancreatitis AcuteGastrointestinal disorders | 2/360 | 0/360 |
| AppendicitisInfections and infestations | 2/360 | 1/360 |
| Event | Axitinib | Placebo |
|---|---|---|
| HypertensionVascular disorders | 231/360 | 91/360 |
| DiarrhoeaGastrointestinal disorders | 168/360 | 52/360 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 149/360 | 21/360 |
| Palmar-Plantar Ertythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 115/360 | 17/360 |
| ProteniureaRenal and urinary disorders | 84/360 | 25/360 |
| FatigueGeneral disorders | 75/360 | 44/360 |
| HypothyroidismEndocrine disorders | 73/360 | 22/360 |
| NasopharyngitisInfections and infestations | 57/360 | 62/360 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 59/360 | 36/360 |
| Back PainMusculoskeletal and connective tissue disorders | 46/360 | 54/360 |
Intent-to-Treat (ITT) population included all randomized participants regardless of whether or not treatment was administered and based on randomized treatment assignment.
| Age, Categorical(Participants) | Axitinib | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 255 | 247 | 502 |
| >=65 years | 108 | 114 | 222 |
| Age, Continuous(Years) | Axitinib | Placebo | Total |
|---|---|---|---|
| Mean | 57.9 ± 10.80 | 58.1 ± 11.33 | 58.0 ± 11.06 |
| Sex: Female, Male(Participants) | Axitinib | Placebo | Total |
|---|---|---|---|
| Female | 83 | 111 | 194 |
| Male | 280 | 250 | 530 |
| Race (NIH/OMB)(Participants) | Axitinib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 264 | 267 | 531 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 91 | 90 | 181 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 3 | 8 |
| Region of Enrollment(participants) | Axitinib | Placebo | Total |
|---|---|---|---|
| South Korea | 87 | 88 | 175 |
| Hong Kong | 6 | 5 | 11 |
| United States | 50 | 47 | 97 |
| Japan | 81 | 79 | 160 |
| China | 63 | 65 | 128 |
| Taiwan | 18 | 19 | 37 |
| France | 23 | 23 | 46 |
| India | 7 | 8 | 15 |
| Spain | 28 | 27 | 55 |
| BMI(Participants) | Axitinib | Placebo | Total |
|---|---|---|---|
| Normal Weight | 187 | 173 | 360 |
| Overweight + Obese | 165 | 175 | 340 |
| Overweight | 115 | 124 | 239 |
| Obese | 50 | 51 | 101 |
| Underweight | 7 | 12 | 19 |
| Missing | 4 | 1 | 5 |
Showing the first 100 of 106 sites across 9 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Apr 2012, a primary completion of Oct 2017 and a completion of May 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2019, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib